Duvelisib is a novel NFAT inhibitor that mitigates adalimumab-induced immunogenicity is a research paper published in Frontiers in Pharmacology (2025). On theSindex it has a DataRank of 0.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NIDDK NIH HHS
Grant: R01 DK140079
NCI NIH HHS
Grant: R01 CA216815
NIGMS NIH HHS
Grant: R35 GM140753
National Institutes of Health
Grant: 1R01CA216815-01A1
Improving the disposition of antileukemic asparaginase after drug-induced immunotoxicity
National Institutes of Health
Grant: 5R01DK140079-02
Mechanistic Study of PEG-asparaginase-Induced Liver Injury
FWCI
0.00
Citation Percentile
0.0%
Fields of Study
Keywords
Sustainable Development Goals